CN115989019B - β肾上腺素能激动剂的形式和组合物 - Google Patents

β肾上腺素能激动剂的形式和组合物

Info

Publication number
CN115989019B
CN115989019B CN202180048013.4A CN202180048013A CN115989019B CN 115989019 B CN115989019 B CN 115989019B CN 202180048013 A CN202180048013 A CN 202180048013A CN 115989019 B CN115989019 B CN 115989019B
Authority
CN
China
Prior art keywords
compound
degrees
present disclosure
peaks
disclosure provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180048013.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN115989019A (zh
Inventor
陈伟
薛冰
大卫·斯科特·卡特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kulassen Therapy
Original Assignee
Kulassen Therapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kulassen Therapy filed Critical Kulassen Therapy
Publication of CN115989019A publication Critical patent/CN115989019A/zh
Application granted granted Critical
Publication of CN115989019B publication Critical patent/CN115989019B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/06—Glycolic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50—Mandelic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/06—Saturated compounds having a carboxyl group bound to a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/90—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl and carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180048013.4A 2020-06-04 2021-06-03 β肾上腺素能激动剂的形式和组合物 Active CN115989019B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034900P 2020-06-04 2020-06-04
US63/034,900 2020-06-04
PCT/US2021/035796 WO2021247934A1 (en) 2020-06-04 2021-06-03 Forms and compositions of a beta adrenergic agonist

Publications (2)

Publication Number Publication Date
CN115989019A CN115989019A (zh) 2023-04-18
CN115989019B true CN115989019B (zh) 2026-01-02

Family

ID=78829944

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180048013.4A Active CN115989019B (zh) 2020-06-04 2021-06-03 β肾上腺素能激动剂的形式和组合物

Country Status (9)

Country Link
US (1) US20230219892A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161496A4 (cg-RX-API-DMAC7.html)
JP (1) JP7734700B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230021075A (cg-RX-API-DMAC7.html)
CN (1) CN115989019B (cg-RX-API-DMAC7.html)
AU (1) AU2021282582A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179993A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022015165A (cg-RX-API-DMAC7.html)
WO (1) WO2021247934A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11607395B2 (en) 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
JP2023541379A (ja) * 2020-09-01 2023-10-02 キュラセン セラピューティクス インコーポレイテッド 神経系の疾患及び障害を改善するための組成物及び方法
US12616667B2 (en) 2021-11-15 2026-05-05 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
CN120583945A (zh) 2023-01-20 2025-09-02 阿托基公司 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019053427A1 (en) * 2017-09-13 2019-03-21 Atrogi Ab HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINO FOR USE IN THE TREATMENT OF HYPERGLYCEMIA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
WO2003072573A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
WO2011133226A2 (en) 2010-04-22 2011-10-27 The Board Of Trustees Of The Leland Stanford Junior University Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
BR112013012994A2 (pt) * 2010-11-24 2016-09-13 Lithera Inc formulações monoterapêuticas de beta-agonista de longa duração, lipofílicas e seletivas e métodos para o tratamento cosmético da adiposidade e saliência de contorno
US9320724B2 (en) 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
US9889087B2 (en) 2014-06-10 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor
BR112018073227A2 (pt) * 2016-05-13 2019-02-19 The Board Of Trustees Of The Leland Stanford Junior University compostos moduladores do receptor adrenérgico e métodos de uso do mesmo
WO2018169742A1 (en) * 2017-03-14 2018-09-20 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibtor
EP3806957A4 (en) * 2018-06-14 2022-03-16 Curasen Therapeutics, Inc. METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS
US10947196B2 (en) * 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019053427A1 (en) * 2017-09-13 2019-03-21 Atrogi Ab HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINO FOR USE IN THE TREATMENT OF HYPERGLYCEMIA

Also Published As

Publication number Publication date
EP4161496A1 (en) 2023-04-12
MX2022015165A (es) 2023-03-01
KR20230021075A (ko) 2023-02-13
CN115989019A (zh) 2023-04-18
JP7734700B2 (ja) 2025-09-05
EP4161496A4 (en) 2024-08-21
US20230219892A1 (en) 2023-07-13
CA3179993A1 (en) 2021-12-09
AU2021282582A1 (en) 2023-02-02
JP2023528450A (ja) 2023-07-04
WO2021247934A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
JP7734700B2 (ja) ベータアドレナリンアゴニストの形態及び組成物
JP7676355B2 (ja) βアドレナリンアゴニストおよびその使用方法
AU2022201709B2 (en) Mono-(acid) salts of 6-aminoisoquinolines and uses thereof
JP2008534470A (ja) Dpp−iv阻害剤の新規な塩及び多形
JP2013505217A (ja) 置換n−フェニル−1−(4−ピリジニル)−1h−ピラゾル−3−アミン類
TW202106680A (zh) Glyt1抑制劑之固體形式
CN100384844C (zh) 黄嘌呤磷酸二酯酶v抑制剂多晶型物
DE69617226T2 (de) Piperidinderivate.
WO2003044024A1 (fr) Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
CN116082259B (zh) 氨基甲酸酯基或氨甲酰基取代的5-ht2b拮抗剂
CN107778336A (zh) 吡喃葡萄糖基衍生物的结晶形式
JP6808088B2 (ja) 純粋な5−ht6受容体アンタゴニストとしてのフルオロピペリジン化合物
AU2018264079B2 (en) New benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands
JP2003535845A (ja) プロパノールアミノテトラリン類、その製造及びそれらを含む組成物
TW200843772A (en) Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
WO2025040140A1 (en) Substituted pyrazol-4-yl urea as kinase inhibitors
TW202521512A (zh) Kv1.3鉀shaker通道阻斷劑之固體形式及其使用方法
WO2001083429A1 (fr) Derives d'aniline
KR20140062471A (ko) 알파 2 아드레날린 수용체의 조절물질로서의 n-(이미다졸리딘-2-일리덴)퀴놀린 유도체
TW201008924A (en) Fluoro-substituted 3,4-diaryl-4,5-dihydro-1H-pyrazole-1-carboxamidine derivatives having CB1-antagonistic activity
JPWO2001083429A1 (ja) アニリン誘導体
JPWO2006121104A1 (ja) ピペリジン環を有するインドール誘導体の結晶およびその製法
HK1140474A (en) Metabolites of (thio) carbamoyl-cyclohexane derivatives
JPWO1998032742A1 (ja) 新規なアミド誘導体及びその医薬組成物
TW200916442A (en) 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1receptor modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant